Travere Therapeutics (TVTX) EPS (Weighted Average and Diluted) Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -25,782.97% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 41.33% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 14.33% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -1.99% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 45.47% |
| 10 | Travere Therapeutics | 4.34 Bn | 4.26 Bn | 102.38 Mn | 34.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34.45% |
| Dec 31, 2025 | 37.62% |
| Sep 30, 2025 | 31.17% |
| Jun 30, 2025 | 48.91% |
| Mar 31, 2025 | 26.83% |
| Dec 31, 2024 | 5.90% |
| Sep 30, 2024 | -5.86% |
| Jun 30, 2024 | -12.45% |
| Mar 31, 2024 | -22.39% |
| Dec 31, 2023 | 22.89% |
| Sep 30, 2023 | 86.41% |
| Jun 30, 2023 | -24.90% |
| Mar 31, 2023 | -317.93% |
| Dec 31, 2022 | -12.96% |
| Mar 31, 2022 | -6.62% |
| Dec 31, 2021 | -67.11% |
| Sep 30, 2021 | 23.92% |
| Jun 30, 2021 | -4.55% |
| Mar 31, 2021 | -27.79% |
| Dec 31, 2020 | -66.31% |
| Sep 30, 2020 | 1.47% |
| Jun 30, 2020 | -19.49% |
| Mar 31, 2020 | 27.29% |
| Dec 31, 2019 | -22.37% |
| Mar 31, 2019 | -131.30% |
| Dec 31, 2018 | -8.74% |
| Sep 30, 2018 | -40.15% |
| Jun 30, 2018 | 8.46% |
| Mar 31, 2018 | -32.92% |
| Dec 31, 2017 | 20.63% |
| Sep 30, 2017 | 18.19% |
| Jun 30, 2017 | 23.85% |
| Mar 31, 2017 | 53.82% |
| Dec 31, 2016 | 21.94% |
| Sep 30, 2016 | -12.09% |
| Jun 30, 2016 | 3.36% |